DFTX — Q2 2026 Financial Report Analysis

Definium Therapeutics (formerly MindMed, renamed in January 2026) is a drug developer with no revenue. Its main drug candidate, DT120, is a tablet form of LSD being tested for anxiety and depression. In Q2 2026 its net loss more than tripled to $159.0 million, or $1.44 per share, but most of that jump was an accounting charge, not spending. The company's share price went from $18.90 to $47.04 during the quarter, which raised the value of warrants it owes to old investors and booked an $86.2 million non-cash loss. The real news in the quarter: the first of its three Phase 3 trials (Emerge, in depression) succeeded, and the company then raised $805 million in new stock. That left about $1.08 billion in cash and investments, which management says will fund operations "into 2030."

At a glance

• $1.08 billion in cash and investments (up from $411.6 million at December 31): enough, by management's estimate, to run the company into 2030 without raising more money.
• $75.1 million operating loss, up 84% from $40.9 million: this is the actual cost of running the business, with research up 63% and overhead up 138% as trials ran and launch planning started.
• Net loss of $159.0 million: $86.2 million of it is a non-cash charge from the higher share price raising the value of outstanding warrants (rights to buy shares at a fixed price), not money that left the company.

Q2 2026 results

Figures are from the company's Form 10-Q for the quarter ended June 30, 2026. The cash comparison is against the December 31, 2025 balance sheet, which is what the filing reports.

Where the money went

Since the company has no sales, the useful questions are how fast it is spending and on what.

Research and development (the cost of running trials, making study drug and paying research staff) rose $18.9 million to $48.7 million. The filing attributes $12.9 million of the increase to the DT120 program and $5.7 million to more internal research staff. Within DT120, outside spending on the depression (MDD) trials rose from $2.0 million to $7.2 million as the second depression trial, Ascend, dosed its first patient in May. The anxiety (GAD) program, where two Phase 3 trials were finishing, cost $22.6 million against $16.9 million a year earlier. The second drug candidate, DT402 (a modified form of MDMA for autism), cost only $0.4 million, which shows how little of the budget goes beyond DT120.

General and administrative costs (management, legal, finance and other overhead) more than doubled to $26.4 million. The filing breaks down the $15.3 million increase: $7.6 million more stock-based pay (much of it the revaluation of directors' cash-settled share units as the stock rose), $2.6 million in corporate and government affairs, $2.0 million in personnel and $1.8 million in "commercial-preparedness," meaning early work to be ready to sell DT120 if it is approved.

Spending is rising quarter to quarter: total operating expenses were about $59.2 million in Q1 2026 and $75.1 million in Q2.

What the headline numbers hide

• The net loss overstates the cash burn. For the first six months, the net loss was $236.1 million, but cash used in operations was $95.4 million. The gap is mostly non-cash items: a $106.3 million warrant charge, $16.8 million of stock-based pay and a $6.2 million revaluation of directors' share units. The cash figure is the better guide to how fast the company uses its money. It works out to roughly $48 million a quarter so far this year, up from about $30 million a quarter in the first half of 2025.
• The warrant charge reflects the stock price. The 2022 warrants are recorded as a liability marked to the share price each quarter. Their value rose from $40.9 million at year-end to $113.0 million, and the filing ties the Q2 swing to the share price rising from $18.90 to $47.04. If the stock falls, this line turns into a gain, as it did in the first half of 2025 (+$4.8 million). Either way it says little about the business. The real cost to shareholders is dilution when the warrants are exercised: 1.57 million shares were issued this way in the first half.
• The share count grew by more than a third. Shares outstanding went from 98.8 million at year-end to 134.4 million, mainly the June offering (23.7 million shares at $34.00) plus pre-funded warrant exercises (9.0 million shares). That is why loss per share widened less (188%) than the total net loss (272%).
• The raise was well timed. It came the day after the Emerge results, at $34.00 a share, compared with $12.25 in the October 2025 offering. The company got about 2.8 times as much money per share issued.
• A royalty obligation went away. In June the company ended its 2020 license with University Hospital Basel and received a fully paid-up, non-exclusive license. The filing says no future milestone or royalty payments are owed. That improves DT120's economics if it reaches market, but the license is no longer exclusive.
• Debt is small. $36.5 million of the K2 term loan is outstanding, and the lender converted $4.5 million into shares during Q2. This is minor next to $1.08 billion of cash.

Takeaway: The quarter's loss is mostly an accounting effect of a share price that more than doubled, and the share price rose on the results that matter. Cash burn is about $48 million a quarter and growing, against $1.08 billion in cash and investments. Money is not the constraint for the next several years. What happens next depends on regulators.

Pipeline: what the trials showed

The Q2 filing reports the first Phase 3 result. A Phase 3 trial is the large, late-stage test that regulators require before approval. Two more trials have read out since the quarter ended, both on the schedule the 10-Q gave ("mid-August" and "September"):

All three trials gave patients a single dose. In Emerge, 35% of patients on DT120 had their depression score cut at least in half by week 6, compared with 7% on placebo, and 24% reached remission, compared with 3%. The company reported that side effects were mostly mild to moderate and occurred on the day of dosing; the most common were visual illusions, hallucinations, anxiety, headache and nausea. In Panorama, patients on the full dose took an average of 6.2 hours to meet the criteria for going home. The FDA granted DT120 a second Breakthrough Therapy designation, for depression, on September 8, which can speed up the regulatory process.

Two caveats are worth keeping in mind. First, the effect in Panorama (0.64) was smaller than in Voyage (0.81). Second, a drug like this produces obvious effects, so patients can often tell whether they got the real drug or a placebo, which makes "blinded" comparisons harder. The FDA will probably look closely at how that was handled.

Outlook

The company plans a pre-NDA meeting with the FDA in Q4 2026 and expects to file a New Drug Application (the formal request for approval) in the first half of 2027. It has two positive anxiety trials, the number regulators usually want for one condition. Depression has one positive trial so far; Ascend, the second, is due to read out in 2027. A PTSD trial (Haven) is planned to start in 2027, and early data on DT402 in autism is expected in 2026. The filing also names a hurdle beyond the FDA: decisions by the DEA and the states on how to schedule (legally classify) the drug, since LSD is currently a controlled substance.

Our view: the financing risk is mostly gone for now, so the main risks are regulatory and commercial. Treatment would require hours of monitoring in a clinic, and how that gets paid for is still an open question. Spending will keep rising: management says R&D will grow throughout 2026, and the new "commercial-preparedness" spending will grow if an approval looks likely. Burn of $60-80 million a quarter in 2027 would still fit the "into 2030" runway. Things to watch in the Q3 10-Q (due around early November): whether operating cash burn moves well above $50 million a quarter, whether G&A keeps climbing as launch planning grows, and the size of the warrant swing, which depends on the share price.